211 related articles for article (PubMed ID: 17402551)
1. Genetic polymorphism of cytochrome P450 and methods for its determination.
Buzková H; Pechandová K; Slanar O; Perlík F
Prague Med Rep; 2006; 107(4):383-93. PubMed ID: 17402551
[TBL] [Abstract][Full Text] [Related]
2. [Genetic polymorphisms of drug metabolizing enzymes].
Fujieda M; Yamazaki H; Kamataki T
Gan To Kagaku Ryoho; 2002 May; 29(5):663-8. PubMed ID: 12040668
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
[TBL] [Abstract][Full Text] [Related]
4. [Genetic polymorphism of drug metabolizing enzymes].
Yokoi T; Kamataki T
Seikagaku; 1997 Oct; 69(10):1196-9. PubMed ID: 9431010
[No Abstract] [Full Text] [Related]
5. Pharmacogenetics: role in modifying drug dosage regimens.
Mah JT; Wong JY; Lee EJ
Ann Acad Med Singap; 2000 Sep; 29(5):628-32. PubMed ID: 11126699
[TBL] [Abstract][Full Text] [Related]
6. SNaPshot for pharmacogenetics by minisequencing.
Bender K
Methods Mol Biol; 2005; 297():243-52. PubMed ID: 15570112
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
8. Polymerase chain reaction-single-strand conformation polymorphism based determination of two major genetic defects responsible for a phenotypic polymorphism of cytochrome P450 (CYP) 2C19 in the Japanese population.
Itoh K; Inoue K; Nakao H; Yanagiwara S; Tada H; Suzuki T
Anal Biochem; 2000 Aug; 284(1):160-2. PubMed ID: 10933870
[No Abstract] [Full Text] [Related]
9. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.
Yokoi T; Kamataki T
Pharm Res; 1998 Apr; 15(4):517-24. PubMed ID: 9587945
[TBL] [Abstract][Full Text] [Related]
11. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
[TBL] [Abstract][Full Text] [Related]
13. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
Liou YH; Lin CT; Wu YJ; Wu LS
J Hum Genet; 2006; 51(10):857. PubMed ID: 16924387
[TBL] [Abstract][Full Text] [Related]
14. [Genotyping of CYP2D6 and CYP2C19].
Slanar O; Drazd'áková M; Babiárová K; Pechandová K; Buzková H; Perlík F; Zima T
Cas Lek Cesk; 2007; 146(9):708-11. PubMed ID: 17966194
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of cytochromes P450.
Hasler JA
Mol Aspects Med; 1999; 20(1-2):12-24, 25-137. PubMed ID: 10575648
[No Abstract] [Full Text] [Related]
16. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.
Ingelman-Sundberg M; Sim SC
Biochem Biophys Res Commun; 2010 May; 396(1):90-4. PubMed ID: 20494117
[TBL] [Abstract][Full Text] [Related]
17. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
18. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
Spigset O; Hedenmalm K; Dahl ML; Wiholm BE; Dahlqvist R
Acta Psychiatr Scand; 1997 Nov; 96(5):379-84. PubMed ID: 9395157
[TBL] [Abstract][Full Text] [Related]
19. Phenotyping of drug metabolism in infants and children: potentials and problems.
Rane A
Pediatrics; 1999 Sep; 104(3 Pt 2):640-3. PubMed ID: 10469807
[No Abstract] [Full Text] [Related]
20. The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study.
Kobylecki CJ; Hansen T; Timm S; Wang A; Jakobsen KD; Sørensen HJ; Rasmussen HB; Werge T
Ther Drug Monit; 2008 Jun; 30(3):265-70. PubMed ID: 18520596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
